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ABSTRACT 
Introduction: Tolperisone is a centrally-acting muscle relaxant that acts by blocking 
voltage-gated sodium and calcium channels. Information on the clinical features of 
tolperisone poisoning is lacking in the literature. The aim of this study was to 
investigate the demographics, circumstances, and clinical features of acute 
overdoses with tolperisone. 
Methods: An observational study of acute overdoses with tolperisone in adults and 
children (<16 y), either alone or in combination with one non-steroidal anti-
inflammatory drug in a dose range not expected to cause central nervous system 
effects, reported to our poison centre between 1995-2013. 
Results: 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults 
(60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained 
asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children 
(33%). There were nine adults (20%) with moderate symptoms, and five adults (11%) 
and three children (10%) with severe symptoms. Signs and symptoms predominantly 
involved the central nervous system: somnolence, coma, seizures, and agitation. 
Furthermore, some severe cardiovascular and respiratory signs and symptoms were 
reported. The minimal dose for seizures and severe symptoms in adults was 1500 
mg. In 11 cases the latency between the ingestion and the onset of symptoms was 
known and was reported to be 0.5 - 1.5 h. 
Conclusions: The acute overdose of tolperisone may be life-threatening, with a rapid 
onset of severe neurological, respiratory, and cardiovascular symptoms. With 
alternative muscle relaxants available, indications for tolperisone should be rigorously 
evaluated. 
 
 
 
 
  
INTRODUCTION 
 
Tolperisone is a centrally acting muscle relaxant1 with an additional vasodilating 
effect.2 This piperidine derivative (1-piperidino-2-methyl-3-(p-tolyl)-propan-3-on) has 
been used for decades mainly in Europe and Asia for the treatment of muscle 
spasticity of neurological origin and muscle pain and muscle spasms due to 
rheumatologic conditions.1 Tolperisone has also been proposed for the treatment of 
peripheral vascular disease.3 
The precise mechanism of the muscle relaxing effect of tolperisone is not fully 
understood. It is supposed that tolperisone inhibits voltage-gated sodium and calcium 
channels mainly in the brainstem and at spinal cord level, resulting in membrane 
stabilization and leading to a reduced spinal mono- and polysynaptic reflex activity.4 
In clinical studies tolperisone was well tolerated with minor side effects including 
nausea, headache, and dizziness.1,5 Nevertheless, anaphylactic reactions have been 
reported and the European Medicines Agency therefore recommended restricting the 
use of tolperisone for the treatment of adults with post-stroke spasticity.6,7 Although 
being a centrally acting muscle relaxant, a sedating effect was not observed in 
therapeutic dose.8 Despite being considered relatively safe in overdose,9 there is a 
forensic publication describing three fatalities due to tolperisone poisoning.10 
Information on the clinical features of tolperisone poisoning is lacking in the literature. 
The aim of this study was to investigate the demographics, circumstances, and 
clinical features of acute overdoses with tolperisone using data reported to a single 
national poison centre during a 19-year period. 
 
 
METHODS 
 
National Poisons Centre operational procedures and data collection methods 
Tox Info Suisse provides 24-hour 7-days-a-week nationwide free medical advice to 
healthcare professionals and the general public (referral population approximately 8 
million) for the management of cases of human poisoning by any substance. 
Demographic and detailed clinical information on exposure cases such as age, 
weight, and sex of the patient, circumstances of the poisoning, ingested doses of all 
substances involved, symptoms and advice provided are recorded in a standardized 
manner by clinical toxicologists who are blinded to any study hypotheses. The case 
records include all reported signs and symptoms. Data are anonymized and 
prospectively entered into an in-house database. Follow-up data including drug 
concentrations, therapeutic interventions and any decontamination measures which 
were performed and clinical course and complications are collected using 
standardized report forms sent to the treating physicians in the days after the initial 
contact. Before finalizing recording into the database, each case was reviewed by a 
senior clinical toxicologist to ensure completeness and correctness of the data. 
 
Study design 
We performed a retrospective review of all acute overdoses involving tolperisone in 
adults and children (<16 years), either alone or in combination with a non-steroidal 
anti-inflammatory drug (NSAID) in a dose not expected to cause central nervous 
system effects, that had been reported to our poisons centre between January 1995 
and December 2013. All cases were reviewed in detail by the first authors before 
they were entered into the study to ensure that they fulfil the inclusion criteria. Doubts 
were resolved by consensus in an expert panel including a senior clinical toxicologist 
and a senior clinical pharmacologist with additional qualification in general internal 
medicine. 
 
Assessment of symptom severity and causal relationship 
The severity of symptoms was graded in accordance with the Poisoning Severity 
Score (PSS) - which has been developed by the European Association of Poison 
Centres and Clinical Toxicologists, the International Programme on Chemical Safety, 
and the European Commission - as ‘minor’, for mild, transient and spontaneously 
resolving symptoms/signs; ‘moderate’, if at least one pronounced or prolonged 
symptom/sign was recorded; ‘severe’, if at least one severe or life-threatening 
symptom/sign was observed, or ‘fatal’, if the overdose was the recorded cause of 
death.11 Cases were assessed for association between symptoms and the 
tolperisone overdose, by an expert panel including a senior clinical toxicologist and a 
senior clinical pharmacologist with additional qualification in general internal 
medicine, using the World Health Organisation Uppsala Monitoring Centre (WHO-
UMC) standardised case causality assessment criteria originally developed for the 
assessment of adverse drug reactions12. Comorbidities and the magnitude of 
overdose were taken into consideration (therapeutic tolperisone dose range in adults 
150 mg three times daily; in children 5–10 mg/kg/day13). Associations were classified 
as `certain`, `likely`, `possible` and `unlikely`, and cases with certain or likely causal 
relationship were included. For the evaluation of the dose-effect relationship, the 
weight of the patient and the ingested tolperisone dose had to be known. 
 
Data analysis 
Descriptive statistics were used to analyze grouped data. Odds ratios (ORs) with 
95% confidence intervals (CIs) and the Fisher exact probability test with two-tailed p-
values were calculated using the software package VassarStats, Vassar College, 
Poughkeepsie, NY, USA (http://vassarstats.net/). Statistical significance was defined 
as p<0.05. 
 
Ethics approval 
A specific ethics approval was not required for this observational study due to the 
nature of the study design according to the regulations of the cantonal ethics 
committee Zurich, Switzerland, which also stated that irreversibly anonymized data 
generated during patient care can be used retrospectively for research purposes 
without obtaining written consent. 
 
 
RESULTS 
 
A search of our database identified 652 cases related to tolperisone ingestion during 
the study period. The exclusion process is reported in Figure 1. A total of 75 cases 
fulfilling all inclusion criteria were available for analysis; of these, 72 were cases of 
single substance overdose and three were tolperisone overdoses with coingestion of 
one NSAID (one case with ibuprofen max. 6000 mg, one with ibuprofen 3600 mg, 
and another with acemetacin 1200 mg). All were acute oral overdoses with film 
coated tablets (50 and 150 mg; no extended-release tablets). The number of acute 
tolperisone overdoses during the 19 years study period is shown in Figure 2. 
 
The demographic characteristics of the patients were as follow: 51 females (68%) 
and 24 males (32%); 45 adults (60%, range 16 - 83 y) and 30 children (40%, range 
1.1 - 15.9 y). Accidental ingestion occurred in all children younger than 12 y (n=22) 
and in three adults, whereas intentional overdose, mostly with suicidal attempt, in all 
other adults (n=42) and children older than 12 (n=8). 
 
Six adults (13%) and 17 children (57%) remained asymptomatic, whereas mild 
symptoms were seen in 25 adults (56%) and 10 children (33%), respectively. There 
were nine adults (20%) with moderate symptoms, and five adults (11%) and three 
children (10%) with severe symptoms (Table 1). Among the three patients who 
coingested a NSAID, there were two severe cases (Table 3) and one asymptomatic 
case. There were no fatalities. 
 
Signs and symptoms predominantly involved the central nervous system, with 
somnolence being the most frequently reported, followed by generalized tonic-clonic 
seizures, coma, and apnoea (Table 2). The main clinical characteristics of the severe 
cases are outlined in Table 3. 
Especially noteworthy are two cases with a rapid onset of severe symptoms in 
toddlers: 
1) a 21-months-old patient ingested up to 2700 mg (225 mg/kg) of tolperisone and 35 
minutes later developed generalized tonic-clonic seizures, apnoea, and cardiac arrest 
at the doctor’s office. Circulation was reestablished after prolonged resuscitation 
efforts, and the child showed severe acidosis (pH 6.98), hypokalemia (2.4 mmol/L), 
and signs of cerebral hypoxia with tetraspasticity. Plasma tolperisone concentration 
14 h after the ingestion was 720 µg/L (therapeutic peak plasma concentrations in 
adults: 64 - 785 µg/L, Tmax 0.9 h).14 After nine month of rehabilitation the patient had 
persistent neurological sequelae such as developmental impairments and muscle 
spasticity. 
2) a 19-months-old patient ingested up to 1500 mg (150 mg/kg) of tolperisone, with 
subsequent vomiting and rapid deterioration of the level of consciousness. One hour 
after the ingestion, the patient presented at the emergency department in a comatose 
state (Glasgow Coma Scale score of 3), showed a respiratory acidosis (pH 6.90), and 
required intubation and mechanical ventilation. A few hours later, the patient was 
extubated and fully recovered. 
 
41 adults (91%) ingested a precisely known dose. The dose range was 300-4500 mg 
in the asymptomatic group (n=5), 900-4500 mg in those with minor toxicity (n=22), 
500-4500 mg in those showing moderate toxicity (n=9), and 1500-15000 mg in those 
with severe toxicity (n=5). The minimal tolperisone dose for seizures was 1500 mg, 
and the minimal dose for coma was 3700 mg in adults. There were 14 children (47%) 
who ingested a known dose: eight remained asymptomatic after ingestion of 6.3-36.0 
mg/kg, and six showed mild symptoms after ingestion of 3.1-83.3 mg/kg. In the 
remaining 20 cases, information about ingested dose was not precise enough to 
allow for inclusion of these cases in the above analysis of dose-effect relationship. 
 
In 11 of the 75 cases (4 mild, 4 moderate, 3 severe) the latency between the 
ingestion and the onset of symptoms was known and was reported to be 30 to 90 
minutes (mean 55). 
 
Early gastrointestinal decontamination was performed significantly more frequently in 
children (15 cases, 50%) than in adults (10, 22%) (OR 3.5; 95% CI, 1.28-9.54; 
p=0.02). It mainly consisted in oral administration of activated charcoal (n= 22) and 
rarely gastric lavage (n=2) or induced emesis (n=1). 
 
 
DISCUSSION 
 
This observational study of tolperisone overdoses reported to a single national 
poison centre illustrates that, although tolperisone is considered to be relatively safe 
without sedative effects at therapeutic dose levels,8 overdose can cause serious 
toxicity, including coma, generalized seizures, severe respiratory depression, and 
cardiac arrest. No clear dose-effect relationship was observed in this study, and this 
is possibly due to the uncertainty on the amounts actually ingested by patients, as is 
the case for most retrospective studies with poison centres data, and the large inter-
individual difference in plasma tolperisone concentrations, which has been reported 
to vary between 64 and 785 µg/L after a therapeutic tolperisone dose of 150 mg, 
although the extrapolation to the overdose setting may be questionable.15 Seizures 
were frequently seen in our patients, and had a rapid onset within the first hour after 
the ingestion. No seizures occurred during the subsequent clinical course. The 
remarkable potential of tolperisone to cause seizures in overdose was also described 
in another study from our centre, and was shown to be comparable with that of 
tramadol, mefenamic acid, citalopram, and venlafaxine.16 
 
The observed cardiovascular symptoms were predominantly mild, although there was 
a case of relevant prolongation of the QTc-interval (500 ms), and this has not been 
previously reported in the literature. The product information reports a case of 
unspecified QT-interval prolongation, which was observed in combination with a 
supraventricular and ventricular arrhythmia after the ingestion of 750 mg of 
tolperisone in a 11-month-old child.9 Furthermore, in our study there was a case of 
cardiac arrest that occurred in a child, but, unfortunately, we have neither further 
information regarding its development, nor an electrocardiogram. 
 
In this study there were no fatal outcomes, although there is a forensic report 
describing tolperisone-related out-of-hospital fatalities: three women, aged 14-41 y, 
were found dead after apparent suicidal drug ingestion, and had post-mortem blood 
tolperisone concentrations of 7-19 mg/L, without other causes for death.10 
 
Activated charcoal and gastric lavage were used for gastrointestinal decontamination 
in a large proportion of our patients, but, unfortunately we are not in a position to 
draw conclusions about its efficacy due to small case numbers and uncontrolled 
settings without plasma concentration measurements. However, on the basis of the 
chemical properties of tolperisone, a good adsorption onto activated charcoal is to be 
expected. Tolperisone has a molecular weight of 281.8 Dalton, meaning that it is 
expected to be readily adsorbed into the 10–1000 Å-sized charcoal pores of current 
activated charcoal products.17 The fact that gastrointestinal decontamination was 
performed in children more frequently than in adults, as we already found in two other 
studies from our centre,18,19 possibly reflects the earlier presentation of children to 
emergency services and the difficulty medical staff have in obtaining an accurate 
account of the amount of drug ingested. In any case, due to the rapid onset of life-
threatening neurological, respiratory, and cardiovascular symptoms in some cases, 
the prompt initiation of emergency measures, even in the out-of-hospital setting, 
seems even more important than gastrointestinal decontamination procedures. 
 
Eperisone, a related compound to tolperisone with a close chemical structure (Figure 
3) and comparable pharmacodynamic properties, seems to have a similar acute 
toxicity profile as tolperisone. Actually, there is a report of a 18-month-old girl who 
developed recurrent seizures, coma, apnoea, and ventricular tachycardia 30 minutes 
after the ingestion of 100 mg of eperisone (therapeutic dose for adults 150 mg/day).20 
Furthermore, similar signs and symptoms as those found in our study were described 
in a case series of 13 eperisone overdoses.21 There is a report of eperisone-related 
prolongation of the QT interval, as we also observed in our study,22 and one of 
torsade de pointes.23 These observations suggest a possible class effect regarding 
the acute toxicity profile of tolperisone and related centrally acting muscle relaxants. 
 
Tolperisone is structurally related to lidocaine (Figure 3) and both substances bind to 
voltage dependent sodium channels.24 Accordingly, we demonstrated that the acute 
toxicity profile of tolperisone shares some similarities with that of local anaesthetic 
agents, in particular the rapid onset of severe neurotoxicity.25,26 The systemic toxicity 
of local anaesthetics has been shown to be related to the time needed to reach the 
maximal plasma concentration,27 which is quite short for tolperisone (Tmax = 0.9 ± 
0.3 h).14 Although severe cardiotoxicity was rarely seen in our study, there might be a 
risk for cardiac arrhythmias, which are a characteristic manifestation of local 
anaesthetic agent toxicity. As acidosis is known to increase local anaesthetic 
toxicity28 it seems plausible that conditions such as seizures and respiratory 
depression, which are observed in tolperisone overdose and are associated with 
acidosis, will further exacerbate tolperisone toxicity. 
 
The interpretation of our findings is limited by the retrospective nature of the study 
design29. In addition, our strict inclusion criteria led to small case numbers. However, 
we are convinced that these restrictions were necessary to be able to interpret the 
findings properly, in particular because we were mostly not able to obtain plasma 
concentrations of tolperisone. A further limitation is due to the fact that we also 
included two severe and one moderate case with coingestion of a NSAID, a drug 
class which is frequently coadministered with tolperisone. However, in all cases the 
NSAID dose was low, and not in a range expected to influence the clinical course. 
 
 
CONCLUSIONS 
 
In conclusion, the acute overdose of tolperisone may be life-threatening, with a rapid 
onset of severe neurological, respiratory, and cardiovascular symptoms. With 
alternative muscle relaxants available, the current indications for tolperisone should 
be rigorously evaluated. 
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